159 related articles for article (PubMed ID: 25154453)
1. Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4.
Kashima K; Watanabe M; Sato Y; Hata J; Ishii N; Aoki Y
Cancer Sci; 2014 Oct; 105(10):1343-50. PubMed ID: 25154453
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
4. Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
Vela M; Bueno D; González-Navarro P; Brito A; Fernández L; Escudero A; Valentín J; Mestre-Durán C; Arranz-Álvarez M; Pérez de Diego R; Mendiola M; Pozo-Kreilinger JJ; Pérez-Martínez A
Front Immunol; 2019; 10():1814. PubMed ID: 31428099
[TBL] [Abstract][Full Text] [Related]
5. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma.
Zhao BC; Wang ZJ; Mao WZ; Ma HC; Han JG; Zhao B; Xu HM
World J Gastroenterol; 2011 May; 17(19):2389-96. PubMed ID: 21633638
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D.
Kashima K; Watanabe M; Satoh Y; Hata J; Ishii N; Aoki Y
Cancer Sci; 2012 Dec; 103(12):2144-52. PubMed ID: 22937829
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.
Libura J; Drukala J; Majka M; Tomescu O; Navenot JM; Kucia M; Marquez L; Peiper SC; Barr FG; Janowska-Wieczorek A; Ratajczak MZ
Blood; 2002 Oct; 100(7):2597-606. PubMed ID: 12239174
[TBL] [Abstract][Full Text] [Related]
8. Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma.
Zhang JP; Lu WG; Ye F; Chen HZ; Zhou CY; Xie X
Int J Gynecol Cancer; 2007; 17(2):478-83. PubMed ID: 17362322
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma.
Diomedi-Camassei F; McDowell HP; De Ioris MA; Uccini S; Altavista P; Raschellà G; Vitali R; Mannarino O; De Sio L; Cozzi DA; Donfrancesco A; Inserra A; Callea F; Dominici C
Clin Cancer Res; 2008 Jul; 14(13):4119-27. PubMed ID: 18593989
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma.
Strahm B; Durbin AD; Sexsmith E; Malkin D
Clin Exp Metastasis; 2008; 25(1):1-10. PubMed ID: 17768666
[TBL] [Abstract][Full Text] [Related]
11. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
12. Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability.
Chu H; Zhou H; Liu Y; Liu X; Hu Y; Zhang J
Int J Biochem Cell Biol; 2007; 39(1):197-205. PubMed ID: 16973405
[TBL] [Abstract][Full Text] [Related]
13. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
14. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression.
Yasuoka H; Kodama R; Tsujimoto M; Yoshidome K; Akamatsu H; Nakahara M; Inagaki M; Sanke T; Nakamura Y
BMC Cancer; 2009 Jul; 9():220. PubMed ID: 19580679
[TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.
Tarnowski M; Grymula K; Liu R; Tarnowska J; Drukala J; Ratajczak J; Mitchell RA; Ratajczak MZ; Kucia M
Mol Cancer Res; 2010 Oct; 8(10):1328-43. PubMed ID: 20861157
[TBL] [Abstract][Full Text] [Related]
16. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway.
Wang J; Cai J; Han F; Yang C; Tong Q; Cao T; Wu L; Wang Z
Int J Gynecol Cancer; 2011 Aug; 21(6):981-7. PubMed ID: 21738044
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma.
Kato M; Kitayama J; Kazama S; Nagawa H
Breast Cancer Res; 2003; 5(5):R144-50. PubMed ID: 12927045
[TBL] [Abstract][Full Text] [Related]
18. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
Yasumoto K; Koizumi K; Kawashima A; Saitoh Y; Arita Y; Shinohara K; Minami T; Nakayama T; Sakurai H; Takahashi Y; Yoshie O; Saiki I
Cancer Res; 2006 Feb; 66(4):2181-7. PubMed ID: 16489019
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice.
Brennecke P; Arlt MJ; Campanile C; Husmann K; Gvozdenovic A; Apuzzo T; Thelen M; Born W; Fuchs B
Clin Exp Metastasis; 2014 Mar; 31(3):339-49. PubMed ID: 24390633
[TBL] [Abstract][Full Text] [Related]
20. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
